US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

38.06

+0.18000.48%

Post-market: 38.060.00000.00%19:30 EDT

Volume:114.36K

Turnover:4.36M

Market Cap:251.20M

PE:- -

High:38.28

Open:38.22

Low:38.01

Close:37.88

52wk High:41.49

52wk Low:22.33

Shares:6.60M

Float Shares:6.60M

Volume Ratio:0.62

T/O Rate:1.73%

Dividend:0.28

Dividend Rate:0.74%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Twist Bioscience Price Target Announced at $45.00/Share by BWS Financial

Moderna Set for 3 Near-Term INT Data Readouts, UBS Says

MT Newswires Live

Twist Bioscience initiated with a Sell at BWS Financial

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

UBS Initiates Coverage on Twist Bioscience With Neutral Rating, $144 Price Target

MT Newswires Live

ProQR Therapeutics doses first participant in AX-0811 clinical trial

Twist Bioscience CEO, CFO to Speak at Baird Global Healthcare Conference Fireside Chat

Bayer initiates Phase II study of BAY 3670549 in patients with AFib

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Evotec initiates clinical trial evaluating JST-018

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Moderately bullish activity in Moderna with shares down 1.79%

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/IDNA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":38.06,"timestamp":1789156800000,"preClose":37.88,"halted":0,"volume":114363,"hourTrading":{"tag":"盘后","latestPrice":38.06,"preClose":38.06,"latestTime":"19:30 EDT","volume":20,"amount":761.1742,"timestamp":1789169407146,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004751847940865884,"floatShares":6600000,"shares":6600000,"eps":0,"marketStatus":"Market Closed","change":0.18,"latestTime":"09-11 16:00:00 EDT","open":38.22,"high":38.28,"low":38.005,"amount":4356036.121553999,"amplitude":0.00726,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":37.88,"sharesOutstanding":5100000,"nav":37.991633,"aum":258343104.4,"dividendRate":0.007365,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":37.8647,"preClose":37.88,"latestTime":"09:12 EDT","volume":4,"amount":150.5941,"timestamp":1789132356897,"change":-0.0153,"changeRate":-0.000404,"amplitude":0.022827},"postHourTrading":{"tag":"盘后","latestPrice":38.06,"preClose":38.06,"latestTime":"19:30 EDT","volume":20,"amount":761.1742,"timestamp":1789169407146,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6184424703621776,"impliedVol":0.1978,"impliedVolPercentile":0.51},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6600000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6184424703621776,"shares":6600000,"dividePrice":0.2803,"high":38.28,"amplitude":0.00726,"preClose":37.88,"low":38.005,"week52Low":22.33,"pbRate":"--","week52High":41.49,"institutionHeld":0,"latestPrice":38.06,"eps":0,"divideRate":0.007365,"volume":114363,"delay":0,"ttmEps":0,"open":38.22,"prevYearClose":26.19,"prevWeekClose":39.77,"prevMonthClose":39.26,"prevQuarterClose":33.75,"fiveDayClose":40.29,"twentyDayClose":35.24,"sixtyDayClose":29.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666598627","title":"CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598627","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598627?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:33","pubTimestamp":1789039980,"startTime":"0","endTime":"0","summary":"Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359400/0/en/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4200","HYLG","UBCP","BK4168","GDOC","IDNA","BK4139","BK4007","MEDX","CMP","NVIB","BK4561","BK4539","ASO","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666640045","title":"Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255","url":"https://stock-news.laohu8.com/highlight/detail?id=2666640045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666640045?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:09","pubTimestamp":1789034986,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B2B36J28.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BBH","RVMD","PTH","IDNA","IE0009355771.USD","CANC","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","IE0009354923.USD","IE00B4R5TH58.HKD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566940","title":"BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566940","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566940?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:32","pubTimestamp":1789029138,"startTime":"0","endTime":"0","summary":"BeOne Medicines FY26 H1 net income climbs to US$464.36 million; revenue rises 32.3% to US$3.22 billionBeOne Medicines posted GAAP net income of US$464.36 million, swinging from profit of US$95.59 mill","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL4kr7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","RVMD","LU0320765992.SGD","CANC","LU0889565916.HKD","IDNA","IE0002141913.USD","IE0009355771.USD","BK0239","IE00BFTCPJ56.SGD","IE0009354923.USD","PTH","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B2B36J28.USD","BBH","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581105","title":"Twist Bioscience Price Target Announced at $45.00/Share by BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581105","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666581105?lang=en_us&edition=fundamental","pubTime":"2026-09-10 05:45","pubTimestamp":1788990300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TWST/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKG","TWST","BK4139","GNOM","IDNA","BK4585","WDNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666311265","title":"Moderna Set for 3 Near-Term INT Data Readouts, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666311265","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666311265?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:58","pubTimestamp":1788969505,"startTime":"0","endTime":"0","summary":"Moderna  is set for three data readouts on its individualized neoantigen therapies, or INT, in the near term, serving as potential stock catalysts for the company, UBS Securities said in a Tuesday note.The next major catalyst is the release of phase 3 data on melanoma at an international conference this fall, investors awaiting efficacy on recurrence-free survival and distant metastasis-free survival, the brokerage said.Likely to follow is the phase 2 data on either renal cell carcinoma or muscle-invasive bladder cancer, potentially in 2027, according to UBS. The next readout is probably a phase 3 update on adjuvant non-small cell lung cancer, the investment firm added.UBS has a neutral rating and $150 price target on Moderna.Price: 137.50, Change: -2.83, Percent Change: -2.02","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4501","MRNY","BK4551","LGHT","MRNX","BK4532","BK4533","BK4139","BK4568","BK4548","GNOM","IDNA","BK4585","MRNA","BK4534","BK4588","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536557","title":"Twist Bioscience initiated with a Sell at BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666536557?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960619,"startTime":"0","endTime":"0","summary":"BWS Financial initiated coverage of Twist Bioscience (TWST) with a Sell rating and $45 price target Twist’s stock surge in August, driven by Anthro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/twist-bioscience-initiated-with-a-sell-at-bws-financial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/twist-bioscience-initiated-with-a-sell-at-bws-financial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TWST","BK4585","BK4139","GNOM","WDNA","BK4588","IDNA","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666907533","title":"IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666907533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666907533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept.  09, 2026 (GLOBE NEWS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358657/0/en/imunon-announces-full-agenda-and-speaker-lineup-ahead-of-2026-r-d-day-highlighting-imnn-001-clinical-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","IMNN","MEDX","GDOC","BK4097","IDNA","HYLG","NVIB","PRGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538213","title":"UBS Initiates Coverage on Twist Bioscience With Neutral Rating, $144 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538213","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538213?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:17","pubTimestamp":1788956271,"startTime":"0","endTime":"0","summary":"Twist Bioscience (TWST) has an average rating of buy and mean price target of $87.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TWST","WDNA","BK4139","GNOM","BK4585","IDNA","ARKG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","AX","LENZ","LU1861217088.USD","BK4007","BK4211","BK4195","BK4139","LU2360107671.USD","MEDX","NVIB","PRQR","BK4539","GDOC","LU1861220207.SGD","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538631","title":"Twist Bioscience CEO, CFO to Speak at Baird Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538631?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:03","pubTimestamp":1788955397,"startTime":"0","endTime":"0","summary":"Twist Bioscience CEO, CFO to speak at Baird Global Healthcare Conference fireside chatTwist Bioscience will join the Baird 2026 Global Healthcare Conference in New York City on Sept. 15, 2026.CEO Emil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL63nZ4z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TWST","WDNA","BK4139","BK4585","GNOM","ARKG","IDNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538313","title":"Bayer initiates Phase II study of BAY 3670549 in patients with AFib","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538313","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538313?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954315,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced the initiation of a global Phase II clinical trial evaluating BAY 3670549, an investigational highly selective G-protein-co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAY","BAYRY","BK4007","MEDX","NVIB","HYLG","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666769587","title":"Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666769587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666769587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952232,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Collegium Pharmaceutical (COLL), Revolution Medicine...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4137","XBI","IE0002141913.USD","LU0128526141.USD","BK4585","LU0109394709.USD","LU0320765992.SGD","BBH","PTH","LU0029874061.USD","RVMD","CANC","IE00B2B36J28.USD","NTLA","IE0009355771.USD","BK4581","IE00BFTCPJ56.SGD","LABU","IE00BJJMRZ35.SGD","BK4535","IE00BJT1NW94.SGD","HCSG","IDNA","COLL","LU0889565916.HKD","LU1861559042.SGD","IE00B4R5TH58.HKD","IE0009354923.USD","BK4588","XLV","BK4556","LU1861558580.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","HYLG","BK4139","BMED","SLE","CCR","FATE","GDOC","IDNA","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587949","title":"Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587949?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","GDOC","HYLG","BK4585","MEDX","BK4588","NVIB","LABU","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558799","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","HYLG","BMED","INN","GDOC","SAT","IDNA","NVIB","MEDX","BK4218","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589922","title":"Evotec initiates clinical trial evaluating JST-018","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589922?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:15","pubTimestamp":1788945324,"startTime":"0","endTime":"0","summary":"Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVO","MEDX","GDOC","HYLG","BK4121","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APXH","BME","IBRN","GNOM","SBIO","IBBQ","GPCR","IBBJ","IBB","RSPH","XPH","CURE","MEDI","SURI","GNMX","JDOC","BBH","FHLC","MDTX","MEDX","BIB","MNTL","SYNB","PBE","PJP","JHMH","LFSC","FBT","PSCH","PTH","HYLG","LLYX","GDOC","WDNA","NVIB","MRNY","PSIL","HRTS","PBPH","TBXU","PINK","FTXH","CANC","IEIH","GSKH","CNCR","FXH","AZNH","IDNA","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372326","title":"Moderately bullish activity in Moderna with shares down 1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372326?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:20","pubTimestamp":1788891611,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Moderna (MRNA), with shares down $2.60 near $142.95. Options volume relatively light with 44k contracts traded and c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-moderna-with-shares-down-1-79-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4501","BK4548","WDNA","MRNA","BK4568","MRNY","BK4588","BK4585","BK4139","BK4532","MRNX","GNOM","BK4534","BK4551","LGHT","BK4533","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372878","title":"Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372878","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372878?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:15","pubTimestamp":1788891334,"startTime":"0","endTime":"0","summary":"• Vertex shares faced volatility and profit-taking after rallying near their 52-week high.\n• The Crinetics acquisition integration will not be non-GAAP accretive until 2029.\n• Technical indicators show a neutral MACD, neutral RSI, and oversold Williams %R.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262156625-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0256863811.USD","IE0002270589.USD","LU2456880835.USD","IE00B2B36J28.USD","LU2462157665.USD","IE00B19Z9Z06.USD","LU1430594728.SGD","LU0109394709.USD","LU0289739699.SGD","LU1585245621.USD","LU2237438978.USD","LU2468319806.SGD","SG9999001176.USD","LU1093756168.USD","VRTX","LU2089984988.USD","IE0002141913.USD","IE0009355771.USD","BIB","IE00BZ9MQY76.HKD","LU1069344957.HKD","LU2236285917.USD","IE00B19Z9P08.USD","SG9999013999.USD","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU0079474960.USD","LU0234570918.USD","IE00BJT1NW94.SGD","BBH","LU0320765992.SGD","TBXU","GNMX","LU1093756325.SGD","BK4567","SGXZ57979304.SGD","BK4532","BK4585","LU0432979614.USD","IBB","IE00B894F039.SGD","BK4139","IBBQ","BK4533","IDNA","IE00BJJMRZ35.SGD","LU0417517546.SGD","LU0823416689.USD","LU0889565916.HKD","LU1035775433.USD","LU1674673691.USD","LU2362541273.HKD","LU2417539215.USD","SG9999001176.SGD","LU0058720904.USD","IE00B4R5TH58.HKD","LU1778281490.HKD","PBE","LU2324357040.USD","LU2362540622.SGD","LU2362541513.USD","IE00B19Z3581.USD","LU1674673428.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FTXH","JHMH","WDNA","MRNY","PJP","XPH","CNCR","IDNA","LENZ","LFSC","JDOC","TBXU","BBH","MNTL","GNOM","PBPH","IBB","PSIL","PBE","GNMX","MEDI","GDOC","FXH","IBBJ","FBT","LLYX","GPCR","MDTX","PINK","MEDX","GSKH","APXH","NVIB","CANC","BBP","SBIO","PSCH","BME","CURE","SURI","RSPH","HYLG","IBBQ","PTH","AZNH","FHLC","BIB","SYNB","HRTS","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}